Stock Ratings / Health Care / NEPH / forecast

CVRX (43) DRIO (36) XTNT (69) TELA (36) ⌘ Pro Terminal →

Nephros Inc. (NEPH) 12-Month Stock Forecast & Price Target Cone

$3.27 +3.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Nephros Inc. (NEPH) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (62% profit margin, 19% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $35.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEPH)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NEPH Position Size: $10,000

Shares at $3.27: 3058.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.68

$8,196

$-1,804 (-18.0%)

12M Consensus BaseTarget $3.49

$10,673

+$673 (+6.7%)

12M Bull Case BreakoutTarget $6.74

$20,612

+$10,612 (+106.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 23● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$4	74%	A
Goldman SachsSector Coverage Lead	BUY	$6	69%	B
JP MorganUS Large-Cap Research	HOLD	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NEPH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.48%📐 HORIZONTAL RANGE

2026-10-30O $3.38H $3.50L $3.17C $3.27VOL 12.3K

RES: $5.66SUP: $2.99SMA50: $3.90SMA200: $3.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEPH Butterfly Map → + Track NEPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.0%/yr Implied 5Y Growth

vs. +32.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEPH)

Health Care Rank #65 of 1016 ⚔️ CVRX vs NEPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEPH vs. CVRX, DRIO, XTNT, TELA)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nephros Inc. (NEPH) ranks #65 by composite RQD confidence (73/100, grade B) and #789 by equity capitalization ($35.5M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEPH ACTIVE Nephros Inc.	B	73/100	29.8x	61.9%	18.9%	+3.16%	$35.5M	Benchmark Subject
CVRX CVRx Inc.	D-	43/100	—	85.3%	-35.0%	+1.79%	$38.0M	/cvrx-vs-neph →
DRIO DarioHealth Corp.	D-	36/100	—	56.6%	-35.0%	-2.93%	$32.4M	/drio-vs-neph →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-neph →
TELA TELA Bio Inc.	D-	36/100	—	67.7%	-35.0%	-5.74%	$41.5M	/tela-vs-neph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001196298

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nephros Inc. (NEPH) reported GAAP revenue of $18.8M (+32.7% vs. FY2024 revenue of $14.2M , and +32.0% cumulative change since FY2023) , GAAP net income of $1.2M, operating cash flow of $1.6M, and free cash flow of $1.6M (+392.5% YoY). On the balance sheet, NEPH closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$18.8M	$1.2M	$1.6M	$1.6M	$13.6M	—
FY2024 (FY)	2024-12-31	$14.2M	$74.0K	-$492.0K	-$547.0K	$11.2M	—
FY2023 (FY)	2023-12-31	$14.2M	-$1.6M	$827.0K	$827.0K	—	—

3. NEPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nephros Inc. (NASDAQ: NEPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $3.27 (+3.16% 1D, market cap $35.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, NEPH ranks #65 in composite RQD confidence.

How does NEPH compare to CVRX and DRIO in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NEPH carries a Roarable B (73/100 RQD), trailing P/E of 29.8x, gross margin of 61.9%, and ROIC of 18.9%. By comparison, CVRX (CVRx Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $38.0M) and DRIO (DarioHealth Corp.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEPH?

Per NEPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001196298), Nephros Inc. generated $18.8M in revenue (+32.7% YoY), $1.2M in net income, and $1.6M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (62% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEPH trading relative to its 50-day, 200-day, and 52-week technical levels?

NEPH last traded at $3.27 (+3.16% on volume of 72,438 shares), positioning the stock -16.15% below its 50-day simple moving average ($3.90) and -10.90% below its 200-day simple moving average ($3.67). Across its 52-week range of $2.66 to $6.42, NEPH sits at the 16.2% percentile with a 14-day RSI of 36.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.86 to $3.68).

NEPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NEPH's 12-month stock price target?

Nephros Inc. (NEPH) carries a 12-month consensus base price target of $3.49 (+6.7% from $3.27), with a bull-case target of $6.74 and a bear-case floor of $2.68.

Is NEPH stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NEPH B (Buy — BUY) with an RQD Confidence score of 73/100.

Direct Sub-Reports: NEPH RQD Cockpit NEPH 12M Forecast NEPH Earnings & Move NEPH Dividends & DRIP NEPH Insiders & 13F NEPH Whale Options NEPH Profit Sankey NEPH News & Why